ID

33086

Beschreibung

Pioglitazone Versus Metformin in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00815399

Link

https://clinicaltrials.gov/show/NCT00815399

Stichworte

Versionen (1)
  1. 26.11.18 26.11.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

26. November 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Type 2 Diabetes NCT00815399

Englisch

Eligibility Type 2 Diabetes NCT00815399

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
men and women aged 30-75 years, with newly-diagnosed type 2 diabetes (according to the ada criteria) and never treated with antihyperglycemic drugs, were selected for the study. inclusion criteria also included a body mass index (bmi) >25 kg/m2, and hba1c level <10%.
Beschreibung

Age | Diabetes Mellitus, Non-Insulin-Dependent | Hypoglycemic Agents Absent | Body mass index | Hemoglobin A1c measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0011860
UMLS CUI [3,1]
C0020616
UMLS CUI [3,2]
C0332197
UMLS CUI [4]
C1305855
UMLS CUI [5]
C0474680
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnancy or breast-feeding
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
any investigational drug within the previous 3 months
Beschreibung

Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0013230
use of agents affecting glycemic control (systemic glucocorticoids, and weight-loss drugs)
Beschreibung

Pharmaceutical Preparations Affecting Glycaemia control | Glucocorticoids, Systemic | Weight-Loss Agents

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C3267174
UMLS CUI [2]
C3540777
UMLS CUI [3]
C0376606
presence of any clinically relevant somatic or mental diseases that anticipated poor adherence to diet regimens
Beschreibung

Disease Somatic | Mental disorders | Adherence Poor Diet therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C2986476
UMLS CUI [2]
C0004936
UMLS CUI [3,1]
C1510802
UMLS CUI [3,2]
C2700379
UMLS CUI [3,3]
C0012159
to minimize the likelihood of including subjects with late-onset type 1 diabetes, candidates with a positive test for anti-gad antibody or with fasting plasma c-peptide less than 0.76 ng/l (<0.25 pmol/l) were excluded
Beschreibung

Late onset Insulin-Dependent Diabetes Mellitus | Anti-GAD antibody positive | Plasma C-peptide level Fasting

Datentyp

boolean

Alias
UMLS CUI [1,1]
C4025592
UMLS CUI [1,2]
C0011854
UMLS CUI [2]
C1167896
UMLS CUI [3,1]
C1303121
UMLS CUI [3,2]
C0015663
also excluded were patients with abnormal laboratory tests, including liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase) greater than 3 times the upper limit of normal, and serum creatinine greater than 123.8
Beschreibung

Laboratory test result abnormal | Elevated liver enzymes | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised | Creatinine measurement, serum

Datentyp

boolean

Alias
UMLS CUI [1]
C0438215
UMLS CUI [2]
C0235996
UMLS CUI [3]
C0151905
UMLS CUI [4]
C0151904
UMLS CUI [5]
C0151849
UMLS CUI [6]
C0201976
μmol/l (1.4 mg/dl).
Beschreibung

ID.8

Datentyp

boolean

Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Type 2 Diabetes NCT00815399

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age | Diabetes Mellitus, Non-Insulin-Dependent | Hypoglycemic Agents Absent | Body mass index | Hemoglobin A1c measurement
Item
men and women aged 30-75 years, with newly-diagnosed type 2 diabetes (according to the ada criteria) and never treated with antihyperglycemic drugs, were selected for the study. inclusion criteria also included a body mass index (bmi) >25 kg/m2, and hba1c level <10%.
boolean
C0001779 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
C0020616 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C1305855 (UMLS CUI [4])
C0474680 (UMLS CUI [5])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
pregnancy or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Investigational New Drugs
Item
any investigational drug within the previous 3 months
boolean
C0013230 (UMLS CUI [1])
Pharmaceutical Preparations Affecting Glycaemia control | Glucocorticoids, Systemic | Weight-Loss Agents
Item
use of agents affecting glycemic control (systemic glucocorticoids, and weight-loss drugs)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C3267174 (UMLS CUI [1,3])
C3540777 (UMLS CUI [2])
C0376606 (UMLS CUI [3])
Disease Somatic | Mental disorders | Adherence Poor Diet therapy
Item
presence of any clinically relevant somatic or mental diseases that anticipated poor adherence to diet regimens
boolean
C0012634 (UMLS CUI [1,1])
C2986476 (UMLS CUI [1,2])
C0004936 (UMLS CUI [2])
C1510802 (UMLS CUI [3,1])
C2700379 (UMLS CUI [3,2])
C0012159 (UMLS CUI [3,3])
Late onset Insulin-Dependent Diabetes Mellitus | Anti-GAD antibody positive | Plasma C-peptide level Fasting
Item
to minimize the likelihood of including subjects with late-onset type 1 diabetes, candidates with a positive test for anti-gad antibody or with fasting plasma c-peptide less than 0.76 ng/l (<0.25 pmol/l) were excluded
boolean
C4025592 (UMLS CUI [1,1])
C0011854 (UMLS CUI [1,2])
C1167896 (UMLS CUI [2])
C1303121 (UMLS CUI [3,1])
C0015663 (UMLS CUI [3,2])
Laboratory test result abnormal | Elevated liver enzymes | Alanine aminotransferase increased | Aspartate aminotransferase increased | Alkaline phosphatase raised | Creatinine measurement, serum
Item
also excluded were patients with abnormal laboratory tests, including liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase) greater than 3 times the upper limit of normal, and serum creatinine greater than 123.8
boolean
C0438215 (UMLS CUI [1])
C0235996 (UMLS CUI [2])
C0151905 (UMLS CUI [3])
C0151904 (UMLS CUI [4])
C0151849 (UMLS CUI [5])
C0201976 (UMLS CUI [6])
ID.8
Item
μmol/l (1.4 mg/dl).
boolean
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video